• Rimonabant (SR141716) in CB1 Research

  2026-09-17

  Rimonabant (SR141716) gives researchers a selective CB1 blockade strategy for separating receptor-driven withdrawal, appetite, inflammation, and neurobehavioral effects. This workflow-focused guide translates sex-aware rat findings into practical dosing, assay, formulation, and troubleshooting decisions.

• CGK733 in TP53-Mutant Glioblastoma Research

  2026-09-17

  CGK733 is a useful chemical probe for examining how DNA-damage signaling intersects with iron-dependent ferroptosis in TP53-mutant glioblastoma. This article translates recent FTH–ITCH findings into a practical, hypothesis-driven assay strategy.

• Catalpol, Aerobic Glycolysis, and Liver Fibrosis

  2026-09-16

  A 2024 Phytomedicine study identifies hepatic stellate-cell glycolysis as a mechanistic target of Catalpol in carbon tetrachloride-induced liver fibrosis. By combining target-engagement assays with metabolic, cellular, and animal analyses, the work links EphA2/FAK/Src signaling to fibrogenic metabolic reprogramming and provides a framework for mechanism-led liver fibrosis research.

• L-Phenylephrine for α1A Signaling Workflows

  2026-09-16

  Build reproducible α1A-focused assays with L-Phenylephrine for cardiomyocyte stress, neural progenitor, and vascular-response studies. A sex-aware cardiovascular framework helps separate receptor activity from baroreflex, hormone, and formulation effects.

• AZD3463: Designing Better ALK Assays

  2026-09-15

  AZD3463 is an ALK/IGF1R inhibitor with strong relevance to neuroblastoma signaling studies. This article provides an assay-centered framework that connects compound identity, pathway readouts, TSSK2 kinase-screening lessons, and translational interpretation without conflating biochemical potency with cellular response.

• RNF166, PARylated Angiomotins, and YAP in CRC

  2026-09-15

  The reference study identifies RNF166 as an E3 ubiquitin ligase that recognizes tankyrase-modified, poly-ADP-ribosylated angiomotins and promotes their destabilization, thereby activating YAP in colorectal cancer. Its domain-mapping, inhibitor, and rescue experiments connect PARylation-dependent substrate recognition to Hippo pathway dysregulation and provide a useful framework for preserving phosphorylation-dependent readouts during follow-up studies.

• Dual SMAD and Wnt Inhibition for iPSC-RGCs

  2026-09-14

  Chavali and colleagues developed a chemically defined, non-genetic method for directing human induced pluripotent stem cells toward retinal ganglion cells through coordinated SMAD and canonical Wnt inhibition. The approach improves differentiation consistency and enables high-purity RGC production, strengthening experimental models for glaucoma and related neurodegenerative disease research.

• Sphingolipid Inhibition Protects Against Ferroptosis

  2026-09-14

  Liu et al. showed that blocking de novo sphingolipid synthesis with myriocin protects neuronal HT22 cells from erastin- or glutamate-induced ferroptosis through HIF-1 activation, rather than by restoring glutathione. The study identifies HIF1α stabilization and metabolic remodeling as a mechanistic basis for neuroprotection and provides a framework for testing ferroptosis-modifying interventions.

• Bufuralol hydrochloride in Intestinal PK Models

  2026-09-13

  Bufuralol hydrochloride connects human intestinal exposure modeling with β-adrenergic pharmacology, offering a practical way to separate epithelial handling from receptor-level effects. A staged 3D-organoid, 2D-monolayer, and functional response workflow helps researchers investigate metabolism, transport, and partial agonist behavior without treating the compound as a purely neutral blocker.

• 6-Thioguanine Blocks EV71 via BIRC3-Linked Autophagy

  2026-09-12

  The 2025 BMC Microbiology study identifies 6-thioguanine as an in vitro inhibitor of EV71 replication and links this activity to reduced BIRC3-mediated complete autophagy. Its high apparent selectivity in HT-29 cells supports further antiviral investigation, while the single-cell-model design leaves important questions about mechanism, genotype coverage, pharmacology, and clinical translation.

• MOG (35-55) and the Next Era of EAE Translation

  2026-09-11

  MOG (35-55) is more than an established EAE inducer: it is a strategic platform for connecting antigen-specific neuroinflammation with emerging immune-signaling mechanisms. By pairing a defined myelin oligodendrocyte glycoprotein peptide with the PARP7–STAT1/STAT2 axis, translational researchers can build more informative autoimmune disease models while maintaining appropriate boundaries around clinical interpretation.

• Superoxide Dismutase Activity Assay Kit Guide

  2026-09-11

  The Superoxide Dismutase (SOD) Activity Assay Kit (SKU K2035) provides a colorimetric way to quantify functional SOD activity in biological fluids by measuring inhibition of WST-1 reduction. It is intended for controlled research workflows, including oxidative stress studies, and should not be used for diagnostic, medical, or clinical decisions.

• Sumatriptan Metabolism Revisited: CYP and MAO Findings

  2026-09-10

  The reference study revisits the accepted view that sumatriptan is metabolized mainly through monoamine oxidase A (MAO A), showing that selected cytochrome P450 enzymes also produce N-desmethyl and N,N-didesmethyl metabolites. Its recombinant-enzyme and HPLC–MS design provides a useful framework for separating CYP-mediated demethylation from MAO-mediated oxidative deamination in drug-metabolism research.

• Dual SMAD/Wnt Inhibition for iPSC-Derived RGCs

  2026-09-10

  Chavali et al. developed a chemically defined, non-genetic strategy for directing induced pluripotent stem cells toward retinal ganglion cells through coordinated inhibition of SMAD and canonical Wnt signaling. The resulting workflow improves lineage purity and reproducibility, providing a useful platform for glaucoma modeling, disease mechanism studies, and evaluation of RGC-directed interventions.

• AAL-993 for Reliable VEGFR Assays

  2026-09-09

  Learn how AAL-993 (SKU C3730) can support reproducible VEGFR-focused viability, proliferation, and angiogenesis experiments. This scenario-based guide covers assay compatibility, concentration selection, solvent control, data interpretation, and practical vendor selection using reported biochemical and preclinical evidence.

8492 records 1/567 page Next 12345 下5页 Last page